Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

Pietro Lapidari; Arnauld Gbenou; Julie Havas; Elise Martin; Barbara Pistilli; Anne Laure Martin; Sibille Everhard; Charles Coutant; Paul Cottu; Anne Lesur; Florence Lerebours; Olivier Tredan; Laurence Vanlemmens; Christelle Jouannaud; Christelle Levy; Olivier Rigal; Marion Fournier; Fabrice Andre; Ines Vaz-Luis; Antonio Di Meglio

doi:10.1016/j.breast.2021.02.014

Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

Pietro Lapidari, Arnauld Gbenou, Julie Havas, Elise Martin, Barbara Pistilli, Anne Laure Martin, Sibille Everhard, Charles Coutant, Paul Cottu, Anne Lesur, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.

langue originale	Anglais
Pages (de - à)	43-48
Nombre de pages	6
journal	Breast
Volume	57
Les DOIs	https://doi.org/10.1016/j.breast.2021.02.014
état	Publié - 1 juin 2021

Accès au document

10.1016/j.breast.2021.02.014

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Lapidari, P., Gbenou, A., Havas, J., Martin, E., Pistilli, B., Martin, A. L., Everhard, S., Coutant, C., Cottu, P., Lesur, A., Lerebours, F., Tredan, O., Vanlemmens, L., Jouannaud, C., Levy, C., Rigal, O., Fournier, M., Andre, F., Vaz-Luis, I., & Di Meglio, A. (2021). Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. Breast, 57, 43-48. https://doi.org/10.1016/j.breast.2021.02.014

@article{a9319d63026a40c28d4f905d06be78be,

title = "Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer",

abstract = "We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.",

keywords = "Breast cancer, Granulocyte-colony stimulating factors, Health-related quality-of-life, Patient-reported outcomes, Survivorship",

author = "Pietro Lapidari and Arnauld Gbenou and Julie Havas and Elise Martin and Barbara Pistilli and Martin, {Anne Laure} and Sibille Everhard and Charles Coutant and Paul Cottu and Anne Lesur and Florence Lerebours and Olivier Tredan and Laurence Vanlemmens and Christelle Jouannaud and Christelle Levy and Olivier Rigal and Marion Fournier and Fabrice Andre and Ines Vaz-Luis and {Di Meglio}, Antonio",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/j.breast.2021.02.014",

language = "English",

volume = "57",

pages = "43--48",

journal = "Breast",

issn = "0960-9776",

}

Lapidari, P, Gbenou, A, Havas, J, Martin, E, Pistilli, B, Martin, AL, Everhard, S, Coutant, C, Cottu, P, Lesur, A, Lerebours, F, Tredan, O, Vanlemmens, L, Jouannaud, C, Levy, C, Rigal, O, Fournier, M, Andre, F, Vaz-Luis, I & Di Meglio, A 2021, 'Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer', Breast, VOL. 57, p. 43-48. https://doi.org/10.1016/j.breast.2021.02.014

TY - JOUR

T1 - Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

AU - Lapidari, Pietro

AU - Gbenou, Arnauld

AU - Havas, Julie

AU - Martin, Elise

AU - Pistilli, Barbara

AU - Martin, Anne Laure

AU - Everhard, Sibille

AU - Coutant, Charles

AU - Cottu, Paul

AU - Lesur, Anne

AU - Lerebours, Florence

AU - Tredan, Olivier

AU - Vanlemmens, Laurence

AU - Jouannaud, Christelle

AU - Levy, Christelle

AU - Rigal, Olivier

AU - Fournier, Marion

AU - Andre, Fabrice

AU - Vaz-Luis, Ines

AU - Di Meglio, Antonio

PY - 2021/6/1

Y1 - 2021/6/1

N2 - We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.

AB - We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.

KW - Breast cancer

KW - Granulocyte-colony stimulating factors

KW - Health-related quality-of-life

KW - Patient-reported outcomes

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85102145276&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2021.02.014

DO - 10.1016/j.breast.2021.02.014

M3 - Article

C2 - 33711699

AN - SCOPUS:85102145276

SN - 0960-9776

VL - 57

SP - 43

EP - 48

JO - Breast

JF - Breast

ER -